Newsfeeds - Spark Newswire

1 minute read

Thinking About Buying Stock In AMD, General Motors Or Sorrento Therapeutics?

Today, 2:52 AM

One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro. WIIMs are a one-sentence description as to why a stock is moving.

AMD

1 minute read

HC Wainwright & Co. Maintains Buy on Sorrento Therapeutics, Lowers Price Target to $26

By Benzinga Newsdesk

Today, 2:52 AM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Sorrento Therapeutics (NASDAQ:SRNE) with a Buy and lowers the price target from $30 to $26.

SRNE

1 minute read

FDA
News

Sorrento Therapeutics Sponsored Study Titled ‘Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 “Long Haul” Pulmonary Compromise (BR)’ Posted To ClinicalTrials.Gov Site; Not Yet Recruiting

By Benzinga Newsdesk

Today, 2:52 AM

https://clinicaltrials.gov/ct2/show/NCT04992247

SRNE

1 minute read

Cramer Advises Viewers On Palantir, SoFi And More

By Craig Jones

Today, 2:52 AM

On CNBC's "Mad Money Lightning Round," Jim Cramer said he doesn't understand why is MKS Instruments, Inc. (NASDAQ: MKSI) trading so cheap. He would be a buyer.

AUPH

1 minute read

Sorrento Therapeutics To Start Testing DAR-T Cell Therapy In Multiple Myeloma Patients

By Vandana Singh

Today, 2:52 AM

The FDA has signed off Sorrento Therapeutics Inc’s (NASDAQ:SRNE) IND application for the Phase 1 clinical testing of its allogeneic anti-CD38…

SRNE

3 minute read

FDA
News

Sorrento Therapeutics Reports Received FDA Authorization To Commence Phase 1 Trial Of Dimeric Antigen Receptor-T Cell Therapy For Relapsed, Refractory Multiple Myeloma

By Benzinga Newsdesk

Today, 2:52 AM

First allogeneic, off-the-shelf anti-CD38 DAR-T cell therapy cleared for Phase 1 clinical trial in Relapsed or Refractory Multiple Myeloma. CD38 DAR-T is the first allogeneic, off-the-shelf clinical-stage cellular

SRNE

1 minute read

Legal
News

Sorrento Therapeutics Files For U.S. Patent Titled ‘DRUG DELIVERY METHODS TARGETING THE LYMPHATIC SYSTEM’

By Benzinga Newsdesk

Today, 2:52 AM

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6752&p=136&f=G&l=50&d=PG01&S1=20210729.PD.&OS=PD/20210729&RS=PD/20210729

SRNE

2 minute read

Lee’s Pharmaceutical Announces First Patient Dosed With Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, As A First-Line Treatment Of Extensive-Stage Small-Cell Lung Cancer

By Benzinga Newsdesk

Today, 2:52 AM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))) and Lee's Pharmaceutical Holdings Limited (HKEX: 950, "Lee's Pharm") announced today that, on July 15, 2021, China Oncology Focus

SRNE

1 minute read

Sorrento Announces That Its Subsidiary Levena, Partner Escugen Have Received Clearance To Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors

By Benzinga Newsdesk

Today, 2:52 AM

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) announced today its partner Escugen Biotechnology Co, Ltd. ("Escugen") and Sorrento's subsidiary Levena (Suzhou) Biopharma Co.,

SRNE

2 minute read

Unusual Options Activity Insight: Sorrento Therapeutics

By Benzinga Insights

Today, 2:52 AM

Shares of Sorrento Therapeutics (NASDAQ:SRNE) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $9.16.

SRNE